论文部分内容阅读
目的:探讨美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的临床疗效。方法:选取2014年5月至2015年4月该院收治的冠心病心力衰竭患者128例作为本次研究的对象,将患者随机分成对照组与治疗组,每组各有64例患者,对照组予以综合治疗,治疗组采用美托洛尔联合曲美他嗪治疗,对比两组患者临床疗效。结果:治疗组治疗总有效率是96.87%,对照组治疗总有效率是84.37%,组间治疗效果对比差异具有显著性(χ~2=5.885,P=0.015)。结论:冠心病心力衰竭患者应用美托洛尔联合曲美他嗪治疗,能显著提高临床疗效,值得在临床上大力推广应用。
Objective: To investigate the clinical effect of metoprolol combined with trimetazidine in patients with heart failure of coronary heart disease. Methods: From May 2014 to April 2015, 128 cases of CHD patients with coronary heart disease admitted to our hospital were selected as the object of this study. The patients were randomly divided into control group and treatment group, each with 64 patients in each group. The control group To be comprehensive treatment, the treatment group metoprolol combined trimetazidine treatment, the clinical efficacy of two groups were compared. Results: The total effective rate was 96.87% in the treatment group and 84.37% in the control group. There was significant difference between the two groups in the treatment effect (χ ~ 2 = 5.885, P = 0.015). Conclusion: The application of metoprolol combined with trimetazidine in patients with coronary heart disease and heart failure can significantly improve the clinical curative effect, which is worth to be popularized and applied clinically.